Bayer (Schweiz) and ASPIVIX collaborate to reduce pain in Women’s Health procedures
16.04.2024
ASPIVIX announces its partnership with Bayer (Schweiz) in Switzerland, aimed at transforming gynaecological procedures. Together, they are introducing Carevix™, a CE-Marked cervical stabilizer designed to minimize pain and bleeding during transcervical procedures, including IUD placement.
 ASPIVIX co-founders Julien Finci and Mathieu Horras
|
 |
The potential pain during IUD insertion impacts millions of women worldwide, largely due to the use of the century-old cervical tenaculum in gynaecological procedures. Carevix™, the suction cervical stabilizer, provides an appealing alternative to currently available tenaculum, filling an important unmet need and has demonstrated clinical effectiveness in reducing both pain and bleeding.
This Swiss collaboration combines Bayer (Schweiz)’s expertise in contraceptive solutions with ASPIVIX’s commitment to modernizing gynaecology. Bayer is a globally recognized leader in women’s health solutions and is one of the world’s top producers of IUDs and their shared goal is to offer women a more comfortable and efficient gynaecological experience, reducing the cases of pain associated with IUD procedures.
ASPIVIX was ranked among the TOP 100 Swiss Startups in 2020, won the last stage of Venture Kick, and participated in Venture Leaders Life Sciences in 2018.
Aspivix's team: Evmorfia Kilimtzidi (Quality Assurance Specialist), Eric Lluvich (Senior Manager Global Operations), Mathieu Horras (CEO and Co-Founder), Julien Fincin (CTO and Co-Founder), and Lara Piers (R&D Project Manager)
This Swiss collaboration combines Bayer (Schweiz)’s expertise in contraceptive solutions with ASPIVIX’s commitment to modernizing gynaecology. Bayer is a globally recognized leader in women’s health solutions and is one of the world’s top producers of IUDs and their shared goal is to offer women a more comfortable and efficient gynaecological experience, reducing the cases of pain associated with IUD procedures.
ASPIVIX was ranked among the TOP 100 Swiss Startups in 2020, won the last stage of Venture Kick, and participated in Venture Leaders Life Sciences in 2018.
Aspivix's team: Evmorfia Kilimtzidi (Quality Assurance Specialist), Eric Lluvich (Senior Manager Global Operations), Mathieu Horras (CEO and Co-Founder), Julien Fincin (CTO and Co-Founder), and Lara Piers (R&D Project Manager)